Ecuador vs Uganda: Average cost of multi drug-resistant tuberculosis treatment
Ecuador
1,121 constant 2022 US$
in 2024
Uganda
1,209 constant 2022 US$
in 2024
Ecuador rank
42nd
Uganda rank
39th
Average cost of multi drug-resistant tuberculosis treatment over time
- Ecuador
- Uganda
How they compare
Uganda currently reports 1,209 constant 2022 US$ against 1,121 constant 2022 US$ in Ecuador, a difference of 88 constant 2022 US$.
That makes Uganda's figure about 1.1 times Ecuador's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Ecuador ahead.
Ecuador ranks 42nd and Uganda ranks 39th of 92 countries.
Across the 2 decades both report, Ecuador averaged higher in 1 and Uganda in 1.
Head to head by decade
| Decade | Ecuador | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 754 constant 2022 US$ | 1,210 constant 2022 US$ | 456 constant 2022 US$ | Uganda |
| 2020s | 1,440 constant 2022 US$ | 1,304 constant 2022 US$ | 136 constant 2022 US$ | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Ecuador or Uganda?
- Uganda, at 1,209 constant 2022 US$ against 1,121 constant 2022 US$ in Ecuador as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Ecuador and Uganda?
- 88 constant 2022 US$, with Uganda ahead.
- How many years of comparable data are there for Ecuador and Uganda?
- 8 years are reported by both, from 2017 to 2024.
- How do Ecuador and Uganda rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Ecuador ranks 42nd and Uganda ranks 39th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.